drugset
Drugs / 124I-evuzamitide
last change May 2025 re-read 3 minutes ago

124I-evuzamitide

also known as p5+14

Peptide

Investigated by
Attralus, Inc. · University of Tennessee Graduate School of Medicine

Trials 1

today NCT06907849 · Ph 2
20262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT06907849 May 2025 → Mar 2027 expected amyloidosis, carpal tunnel syndrome, lumbar spinal stenosis University of Tennessee Graduate School of Medicine Enrolling by invitation No outcome recorded

Press releases naming this drug 3 releases

DateIssuerRelease
2025-01-15 Attralus, Inc. Attralus Announces Enrollment of First Patient in Phase 3 Trial for the Pan-Amyloid Diagnostic 124I-evuzamitide (AT-01) for Cardiac Amyloidosis attralus.com ↗
2024-08-05 Attralus, Inc. Attralus Receives Breakthrough Therapy Designation for its Pan-Amyloid Diagnostic PET Imaging Candidate 124I-evuzamitide (AT-01) for Cardiac Amyloidosis attralus.com ↗
2023-10-02 Attralus, Inc. Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at the 28th Annual Scientific Session of the American Society of Nuclear Cardiology attralus.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as 124I-evuzamitide ClinicalTrials.gov intervention name — accepted as the source's own label NCT06907849 ↗
Known as p5+14 “124I-evuzamitide is an iodine-124 (124I) labeled 45 L-amino acid peptide (also known as p5+14) suitable for single dose PET/CT imaging.” NCT06907849 ↗
Modality Peptide “45 L-amino acid peptide” NCT06907849 ↗
Route Intravenous “by IV push” NCT06907849 ↗